Home Blood Pressure Monitoring Project
Launched by KAISER PERMANENTE · Jul 13, 2010
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
STUDY OBJECTIVES:
Primary:
• To determine the proportion of patients in each group who achieve their target BP goals at 6 months, according to national clinical practice guidelines
Secondary:
The following parameters will be evaluated between groups:
* Change in BP measures between baseline and at 6 months
* Proportion of patients who are receiving antihypertensive treatments in accordance to national clinical practice guidelines
* Adherence to hypertensive medication regimen during the 6-month follow-up period
* Patient satisfaction with the care model.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 to 85 years At least 1 diagnosis for hypertension,
- • Receive primary care from one of the participating clinics,
- • The two most recent BPs documented within that last 24 months are elevated (SBP\>140 and/or DBP\>90)
- • Receiving \< 3 antihypertensive medications, and
- • Have access to a computer with a USB port.
- Exclusion Criteria:
- • Pregnant, or breast-feeding,
- • Patients on dialysis or being followed by nephrology,
- • Patients with coronary artery disease, given these patients are already followed by the Clinical Pharmacy Cardiac Risk Service (CPCRS),
- • On KPCO "Do Not Call" or deceased list,
- • PCP does not give permission to include patient in the study,
- • BP is at or below target at the baseline study visit,
- • Not English-speaking.
About Kaiser Permanente
Kaiser Permanente is a leading integrated health care organization that combines a health plan with a network of hospitals and physicians to provide comprehensive medical services. With a strong commitment to advancing medical research and improving patient care, Kaiser Permanente sponsors clinical trials across various therapeutic areas. The organization emphasizes innovative approaches to health care, leveraging its extensive data and resources to support evidence-based treatments and enhance patient outcomes. Through its rigorous research initiatives, Kaiser Permanente aims to contribute to the advancement of medical knowledge and the development of new therapies that benefit diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Denver, Colorado, United States
Patients applied
Trial Officials
David J Magid, MD, MPH
Principal Investigator
Kaiser Permanente
Kari Olson, PharmD
Principal Investigator
Kaiser Permanente
Sarah J Billups, PharmD
Principal Investigator
Kaiser Permanente
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials